Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component
- PMID: 17238183
- DOI: 10.1002/cncr.22476
Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component
Abstract
Background: Tyrosine kinase domain (TKD) gene mutations of the epidermal growth factor receptor gene (EGFR) have proven to be clinically significant in nonsmall-cell lung cancer (NSCLC), particularly in adenocarcinoma. However, TKD mutations together with deletion mutations in the extracellular domain of EGFR (EGFRvIII) have not been fully investigated in NSCLC except for adenocarcinoma. The present study sought to gain further insight into the significance of EGFR mutations in NSCLC by focusing on nonadenocarcinoma NSCLC.
Methods: EGFR TKD mutations were investigated using direct sequencing and mutation-specific polymerase chain reaction (PCR), and EGFRvIII mutations were examined using reverse transcriptase-PCR in samples from 42 NSCLC patients and 6 NSCLC cell lines excluding adenocarcinoma.
Results: EGFR TKD mutations were detected in 1 of 7 (14%) squamous-cell carcinomas with an adenocarcinoma component and 2 of 4 (50%) adenosquamous carcinomas. In contrast, EGFR TKD mutations were not identified in 24 pure squamous-cell carcinomas without any adenocarcinoma component, 7 large-cell carcinomas, or 6 cell lines. EGFRvIII was detected solely in 1 of 7 large-cell carcinomas (14%), but not in 31 squamous-cell carcinomas, 4 adenosquamous carcinomas, or 6 cell lines.
Conclusions: These results suggest that EGFR TKD mutations are found in NSCLCs with an adenocarcinoma element. Patients with such lesions are thus considered candidates for molecular therapies targeting EGFR.
Similar articles
-
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.Cancer Lett. 2006 Jun 8;237(1):89-94. doi: 10.1016/j.canlet.2005.05.026. Epub 2005 Jul 18. Cancer Lett. 2006. PMID: 16029927
-
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.Clin Cancer Res. 2005 May 15;11(10):3750-7. doi: 10.1158/1078-0432.CCR-04-1981. Clin Cancer Res. 2005. PMID: 15897572
-
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.J Clin Oncol. 2005 Feb 1;23(4):857-65. doi: 10.1200/JCO.2005.08.043. J Clin Oncol. 2005. PMID: 15681531
-
[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].Zhonghua Zhong Liu Za Zhi. 2017 Feb 23;39(2):90-93. doi: 10.3760/cma.j.issn.0253-3766.2017.02.003. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28219201 Review. Chinese.
-
EGFR inhibitors: what have we learned from the treatment of lung cancer?Nat Clin Pract Oncol. 2005 Nov;2(11):554-61. doi: 10.1038/ncponc0341. Nat Clin Pract Oncol. 2005. PMID: 16270096 Review.
Cited by
-
Analysis of real-word mutations of lung cancer driver genes in five regions of China.Transl Cancer Res. 2019 Nov;8(7):2581-2592. doi: 10.21037/tcr.2019.10.28. Transl Cancer Res. 2019. PMID: 35117015 Free PMC article.
-
Treatment for Patients With Early Stage Adenosquamous Lung Cancer.JTO Clin Res Rep. 2020 Mar 4;1(2):100021. doi: 10.1016/j.jtocrr.2020.100021. eCollection 2020 Jun. JTO Clin Res Rep. 2020. PMID: 34589928 Free PMC article.
-
How should molecular findings be integrated in the classification for lung cancer?Transl Lung Cancer Res. 2020 Oct;9(5):2245-2254. doi: 10.21037/tlcr-20-153. Transl Lung Cancer Res. 2020. PMID: 33209647 Free PMC article. Review.
-
Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR.Int J Mol Sci. 2019 Aug 17;20(16):4020. doi: 10.3390/ijms20164020. Int J Mol Sci. 2019. PMID: 31426517 Free PMC article.
-
Research progress of the clinicopathologic features of lung adenosquamous carcinoma.Onco Targets Ther. 2018 Oct 16;11:7011-7017. doi: 10.2147/OTT.S179904. eCollection 2018. Onco Targets Ther. 2018. PMID: 30410358 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous